These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18830255)

  • 1. The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia.
    Toki T; Kanezaki R; Adachi S; Fujino H; Xu G; Sato T; Suzuki K; Tauchi H; Endo M; Ito E
    Leukemia; 2009 Jan; 23(1):95-103. PubMed ID: 18830255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate.
    Wang CH; Anderson N; Li SH; Szmitko PE; Cherng WJ; Fedak PW; Fazel S; Li RK; Yau TM; Weisel RD; Stanford WL; Verma S
    Circ Res; 2006 Sep; 99(6):617-25. PubMed ID: 16931795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
    Brink DS
    Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chrysin inhibited stem cell factor (SCF)/c-Kit complex-induced cell proliferation in human myeloid leukemia cells.
    Lee SJ; Yoon JH; Song KS
    Biochem Pharmacol; 2007 Jul; 74(2):215-25. PubMed ID: 17493588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA1 mutations in acute leukemia in children with Down syndrome.
    Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
    Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blasts in transient leukaemia in neonates with Down syndrome differentiate into basophil/mast-cell and megakaryocyte lineages in vitro in association with down-regulation of truncated form of GATA1.
    Miyauchi J; Ito Y; Tsukamoto K; Takahashi H; Ishikura K; Sugita K; Miyashita T
    Br J Haematol; 2010 Mar; 148(6):898-909. PubMed ID: 20064153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
    Wang LH; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
    Kosmider O; Denis N; Dubreuil P; Moreau-Gachelin F
    Oncogene; 2007 May; 26(26):3904-8. PubMed ID: 17173066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells.
    Liu XY; Yang YF; Wu CT; Xiao FJ; Zhang QW; Ma XN; Li QF; Yan J; Wang H; Wang LS
    Biochem Biophys Res Commun; 2010 Mar; 393(4):637-42. PubMed ID: 20153728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-apoptotic action of stem cell factor on oocytes in primordial follicles and its signal transduction.
    Jin X; Han CS; Yu FQ; Wei P; Hu ZY; Liu YX
    Mol Reprod Dev; 2005 Jan; 70(1):82-90. PubMed ID: 15515061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway.
    Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
    Dig Dis Sci; 2007 Sep; 52(9):2292-300. PubMed ID: 17410437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.